Drug company discontinues next-gen flu vaccine development as flu cases rise

Drug company discontinues next-gen flu vaccine development as flu cases rise

French drug company Sanofi announced it’s discontinuing research and development for its next-generation mRNA flu vaccine. The company shared the news in an earnings document, saying it was ending the phase one trial.  The firm did not disclose why it was discontinuing the trial, other than stating it was deprioritizing mRNA immunizations. However, Sanofi’s CEO stressed that it “remains fully committed to mRNA technology as a key part of our mul…

Sanofi Scraps Plan To Develop Next Generation mRNA Seasonal Flu Vaccine

Smederevac / iStock French drug company Sanofi yesterday announced it has discontinued development of its next-generation seasonal flu vaccine based on mRNA technology but will continue to pursue a pandemic flu vaccine. Sanofi reported in its 2025 earnings documents that it was discontinuing its mRNA flu vaccine phase 1 trial. “Sanofi has deprioritized its mRNA-based seasonal flu vaccine program and does not anticipate launching an mRNA-based se…